Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by WealthPLAN Partners LLC

WealthPLAN Partners LLC cut its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 23.0% during the second quarter, HoldingsChannel.com reports. The fund owned 603 shares of the medical equipment provider’s stock after selling 180 shares during the period. WealthPLAN Partners LLC’s holdings in Intuitive Surgical were worth $268,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Advisors Asset Management Inc. boosted its stake in Intuitive Surgical by 18.1% during the 1st quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider’s stock worth $2,945,000 after purchasing an additional 1,129 shares during the last quarter. Public Employees Retirement System of Ohio lifted its stake in shares of Intuitive Surgical by 5.4% in the fourth quarter. Public Employees Retirement System of Ohio now owns 191,283 shares of the medical equipment provider’s stock worth $64,531,000 after buying an additional 9,869 shares in the last quarter. HCR Wealth Advisors boosted its position in Intuitive Surgical by 26.3% during the fourth quarter. HCR Wealth Advisors now owns 1,042 shares of the medical equipment provider’s stock worth $352,000 after acquiring an additional 217 shares during the last quarter. Artisan Partners Limited Partnership grew its stake in Intuitive Surgical by 53.5% during the 4th quarter. Artisan Partners Limited Partnership now owns 63,851 shares of the medical equipment provider’s stock valued at $21,541,000 after acquiring an additional 22,264 shares in the last quarter. Finally, SWP Financial LLC acquired a new stake in Intuitive Surgical in the 4th quarter valued at about $255,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Trading Down 1.6 %

ISRG stock opened at $483.32 on Wednesday. The business’s fifty day moving average price is $465.50 and its 200 day moving average price is $423.39. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $496.18. The company has a market capitalization of $171.43 billion, a PE ratio of 87.24, a P/E/G ratio of 5.41 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The company had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. During the same period in the prior year, the firm earned $1.18 earnings per share. The business’s revenue for the quarter was up 14.5% compared to the same quarter last year. Research analysts predict that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Insiders Place Their Bets

In other Intuitive Surgical news, insider Mark Brosius sold 2,115 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $491.91, for a total value of $1,040,389.65. Following the completion of the transaction, the insider now owns 295 shares in the company, valued at $145,113.45. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Intuitive Surgical news, Director Amy L. Ladd sold 450 shares of the company’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $490.28, for a total transaction of $220,626.00. Following the sale, the director now owns 821 shares in the company, valued at approximately $402,519.88. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Mark Brosius sold 2,115 shares of Intuitive Surgical stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $491.91, for a total value of $1,040,389.65. Following the completion of the transaction, the insider now owns 295 shares of the company’s stock, valued at approximately $145,113.45. The disclosure for this sale can be found here. Insiders have sold a total of 53,120 shares of company stock worth $25,528,753 in the last ninety days. 0.90% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have recently weighed in on ISRG. JPMorgan Chase & Co. boosted their target price on Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a report on Friday, July 19th. Morgan Stanley boosted their price objective on Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. The Goldman Sachs Group began coverage on Intuitive Surgical in a research note on Thursday, May 30th. They issued a “buy” rating and a $500.00 target price for the company. Piper Sandler boosted their price target on shares of Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a research report on Friday, July 19th. Finally, BTIG Research raised their price objective on shares of Intuitive Surgical from $469.00 to $494.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $446.45.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.